Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation

Summary

Colistin is a lipopeptide antibiotic administered as an inactive prodrug - colistin methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity dependent on plasma concentrations. The number of patients with these types of infections, as well as the number of patients requiring extracorporeal membrane oxygenation (ECMO) support for severe respiratory failure, increased significantly in association with COVID-19-induced infections. ECMO can generally affect the pharmacokinetics of drugs by creating a new compartment.

Timeline

Start

2022-09-01

Primary completion

2024-01-19

Completion

2024-01-19

Publications

• Suk P, Rychlickova J, Souckova L, Kubickova V, Urbanek K. Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial - a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial. BMJ Open. 2023 Jul 30;13(7):e071649. doi: 10.1136/bmjopen-2023-071649.

Drugs

Indications

No indication recorded.